Short answer
Apogee Therapeutics, Inc. (APGE) filed its Q3 2025 10-Q quarterly report on Nov 10, 2025 for the quarter ended Sep 30, 2025.
Q3 2025 key financials · XBRL
- Net income
- −$65M
- −32.6% YoY · +1.6% QoQ
- EPS (diluted)
- −$1.11
- −27.6% YoY · +1.8% QoQ
Source: XBRL data from the Apogee Therapeutics, Inc. (APGE) Q3 2025 10-Q on SEC EDGAR. USD.
Apogee Therapeutics, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New geopolitical risk from conflicts involving Russia, Ukraine, Israel, and Hamas impacting financial markets and capital raising ability
- Updated financial risk: net loss $186.5M for nine months ended Sep 30, 2025; cash runway now into second half of 2028
- Regulatory risk: FDA may require additional preclinical/clinical studies or impose stricter approval conditions delaying trials
- Operational risk: patient enrollment challenges due to competition from approved products and other clinical trials may delay development
- Competitive risk: significant competitors with greater resources, risks of biosimilars entering market earlier affecting commercial success
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Apogee Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.